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Summary
Blephariphimosis, ptosis, and epicanthus inversus syndrome (BPES) is a complex eyelid malformation invariably characterized by four major features:
blepharophimosis, ptosis, epicanthus inversus, and telecanthus. BPES type I includes the four major features and premature ovarian insufficiency (POI); BPES type II includes only
the four major features. Other ophthalmic manifestations that can be associated with BPES include lacrimal duct anomalies, amblyopia, strabismus, and refractive errors. Minor
features include a broad nasal bridge, low-set ears, and a short philtrum. Individuals with BPES and an intragenic FOXL2 pathogenic variant are expected to have normal
intelligence, in contrast to affected individuals with cytogenetic rearrangements that involve FOXL2 and additional genes.
The diagnosis of BPES is primarily based on clinical findings. Occasionally individuals with BPES have cytogenetic rearrangements, such as interstitial
deletions and translocations involving 3q23. FOXL2 is the only gene currently known to be associated with BPES.
Treatment of manifestations: Timing of eyelid surgery involves balancing the benefits of early surgery to prevent deprivation amblyopia versus late surgery to
allow for more reliable ptosis measurements. Surgery traditionally involves a medial canthoplasty for correction of the blepharophimosis, epicanthus inversus, and telecanthus at age
three to five years, typically followed a year later by ptosis correction; recently, a one-stage surgical procedure has been described. Premature ovarian failure is treated with
hormone replacement therapy; fertility is addressed with reproductive technologies such as embryo donation and egg donation.
Surveillance: Ophthalmic follow up depends on age, procedures performed in the past, and results of visual acuity testing. Endocrinologic and gynecologic follow up are advised
for affected females.
BPES is usually inherited in an autosomal dominant manner; autosomal recessive inheritance has been reported in one consanguineous family. For
autosomal dominant inheritance: Each child of an individual with BPES has a 50% chance of inheriting the FOXL2 pathogenic variant. Prenatal testing for pregnancies at increased
risk is possible if the pathogenic variant in the family has been identified; however, requests for prenatal testing for conditions such as BPES are not common.
Diagnosis
Clinical Diagnosis
The diagnosis of blepharophimosis syndrome (BPES) is based primarily on the following four clinical findings, which are present at birth [Oley & Baraitser 1995]:
Blepharophimosis. Narrowing of the horizontal aperture of the eyelids. In normal adults, the horizontal palpebral fissure measures 25-30 mm; in individuals with BPES, it
generally measures 20-22 mm.
Ptosis. Drooping of the upper eyelid causing a narrowing of the vertical palpebral fissure. In individuals with BPES, ptosis is secondary to dysplasia of the musculus levator
palpebrae superioris. To compensate for the ptosis, affected individuals:
Use the musculus frontalis, wrinkling the forehead to draw the eyebrows upward, which results in a characteristic facial appearance
Tilt their head backward into a chin-up position
Epicanthus inversus. A skin fold arising from the lower eyelid and running inwards and upwards.
Telecanthus. Lateral displacement of the inner canthi with normal interpupillary distance.
Note: A study of ten individuals with molecularly confirmed BPES showed that all had lateral displacement of the inferior punctum (i.e., in the lower eyelid) resulting from a
temporal displacement of the entire lower eyelid. This proved to be an important anatomical hallmark in the diagnosis of BPES [Decock et al 2011a].
Two types of blepharophimosis syndrome have been described [Zlotogora et al 1983]:
BPES type I includes the four major features and female infertility caused by premature ovarian insufficiency (POI).
BPES type II includes only the four major features.
Testing
Females with premature ovarian insufficiency (POI) have:
Endocrinologic findings of hypergonadotropic hypogonadism:
Elevated serum concentrations of follicle-stimulating hormone (FSH) and luteinizing hormone (LH)
Decreased serum concentrations of estradiol and progesterone
A small hypoplastic uterus and streak ovaries on pelvic ultrasound examination
Cytogenetic testing. Cytogenetic rearrangements involving 3q23 (i.e., unbalanced translocations and interstitial deletions) causing BPES have been reported [Fukushima et al
1991, Jewett et al 1993, Boccone et al 1994, Lawson et al 1995, De Baere et al 1999, Praphanphoj et al 2000, de Ru et al 2005, Alao et al 2012, González-González et al 2012
and references therein, Schlade-Bartusiak et al 2012]. Such cytogenetic rearrangements are estimated to occur in a very small fraction of individuals with BPES [Beysen et al
2009].
Molecular Genetic Testing
Gene. FOXL2 is the only gene currently known to be associated with BPES (Table 1).
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Table 1.
Summary of Molecular Genetic Testing Used in Blepharophimosis, Ptosis, and Epicanthus Inversus
Gene Test Method
Proportion of Probands with a Pathogenic Variant Detectable by This
Method 
FOXL2
Sequence analysis 72% 
Deletion/duplication analysis 10%-15% 
Regulatory regions extragenic to
FOXL2
Deletion/duplication analysis of regions upstream of
FOXL2 
5% 
See Table A. Genes and Databases for chromosome locus and protein. See Molecular Genetics for information on allelic variants detected in this gene.
The detection rate using sequence analysis and MLPA is around 82% in familial as well as in simplex cases (i.e., a single occurrence in a family) [De Baere et al 2003, Beysen et al 2005,
Beysen et al 2009].
Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic
deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of
sequence analysis results, click here.
De Baere et al [2003], Beysen et al [2008a], Beysen et al [2009]
Testing that identifies exon or whole-gene deletions/duplications not detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA. Included in the variety
of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this
gene/chromosome segment.
Multiplex ligation-dependent probe amplification (MPLA) detected partial- or whole-gene deletions in approximately 10% of individuals with typical BPES [Beysen et al 2005, Beysen et al
2009].
Cytogenetic rearrangements involving 3q23 (i.e., unbalanced translocations and interstitial deletions) that cause BPES are often accompanied by additional findings, such as microcephaly,
intellectual disability, and growth delay [Fukushima et al 1991, Jewett et al 1993, Boccone et al 1994, Lawson et al 1995, De Baere et al 1999, Praphanphoj et al 2000, de Ru et al 2005
and references therein, Alao et al 2012, González-González et al 2012, Schlade-Bartusiak et al 2012]. Note: Balanced translocations involving 3q23 lead to classic BPES type I or II
without additional findings.
MLPA and other methods for deletion/duplication analysis (see footnote 6) may detect partial-, whole-, or contiguous-gene deletions or upstream regulatory deletions, depending on the
experimental design [Beysen et al 2009, D'haene et al 2009].
Beysen et al [2005], Beysen et al [2009], D'haene et al [2009], Verdin et al [2013]
Testing Strategy
To confirm the diagnosis in a proband
Molecular genetic testing of FOXL2, including sequence analysis and deletion/duplication analysis
If no FOXL2 pathogenic variant or genomic rearrangement of FOXL2 and neighboring region(s) can be identified on molecular genetic testing, chromosome analysis may be
considered depending on the family history and the individual’s phenotype (e.g., chromosomal microarray to screen for copy number variants in targeted regulatory regions
5’ to FOXL2 and karyotyping to screen for chromosomal structural rearrangements such as balanced translocations or inversions).
In persons with BPES-like phenotypes without a FOXL2 pathogenic variant or genomic rearrangement of FOXL2 and neighboring region(s), whole-genome chromosomal
microarray to screen for copy number variants [Gijsbers et al 2008] is recommended to identify the underlying genetic cause of the phenotype (see Genetically Related
Disorders).
Clinical Characteristics
Clinical Description
Blepharophimosis syndromes (BPES) type I and type II are a complex eyelid malformation characterized by four major features, all present at birth: blepharophimosis, ptosis,
epicanthus inversus, and telecanthus. BPES type I also includes female infertility caused by premature ovarian insufficiency (POI).
Other features frequently observed in both BPES type I and type II are a broad nasal bridge, low-set ears, and a short philtrum.
Associated ophthalmic manifestations include dysplastic eyelids (lack of eyelid folds and thin skin); S-shaped border of the upper eyelid and abnormal downward concavity of the
lower eyelid with lateral ectropion; and nasolacrimal drainage problems caused by lateral displacement, duplication, or stenosis of the lacrimal puncta.
A retrospective study in 204 individuals with BPES showed manifest strabismus in 20%, a significant refractive error in 34%, and bilateral or unilateral amblyopia in 21% and 20%,
respectively [Dawson et al 2003]. The incidences of strabismus, refractive errors (anisometropic hypermetropia and myopia), and amblyopia are higher in individuals with BPES
than in the general population [Beckingsale et al 2003, Dawson et al 2003, Choi et al 2006].
Secondary sexual characteristics are usually normal in both BPES type I and type II.
In BPES type I, menarche is usually normal, followed by oligomenorrhea and secondary amenorrhea.
Individuals with BPES who have an intragenic FOXL2 pathogenic variant (in contrast to individuals with a contiguous gene deletion that includes FOXL2) are expected to have
normal intelligence.
Genotype-Phenotype Correlations
Pathogenic variants predicted to result in proteins truncated before the polyalanine tract preferentially lead to POI (BPES type I). Note: The need for careful interpretation of
genotype-phenotype correlations is illustrated by the co-occurrence of BPES type I and isolated POI in a three-generation family.
Polyalanine expansions preferentially lead to BPES type II. The first case with a positive correlation between the size of the polyalanine expansion, its dosage, and the penetrance
of the BPES phenotype was reported by Nallathambi et al [2007].
Click here (pdf) for additional findings observed with some FOXL2 pathogenic variants.
Penetrance
To date, almost all individuals heterozygous for a FOXL2 pathogenic variant have the BPES phenotype; thus, penetrance is nearly complete for the eyelid phenotype.
The exception is a consanguineous Indian family in which heterozygotes for a short polyalanine expansion of 19 alanines are unaffected, but homozygotes have typical BPES (with
documented POI in one female) [Nallathambi et al 2007] (see Molecular Genetics).
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Prevalence
The prevalence of BPES is unknown.
No differences in prevalence based on sex, race, or ethnicity have been reported.
Genetically Related (Allelic) Disorders
Nonsyndromic premature ovarian insufficiency (POI). Considering that POI is part of the phenotypic spectrum of FOXL2 pathogenic variants, FOXL2 was assumed to be a
possible candidate gene for nonsyndromic POI [Crisponi et al 2001, Prueitt & Zinn 2001]. Novel FOXL2 missense variant p.Gly187Asp was found in a woman with POI in the
absence of BPES [Laissue et al 2009]. The subcellular localization of the mutant protein was normal but the transactivation capacity of the mutant protein on two ovary-specific
reporter promoters proved to be lower than that of normal FOXL2 protein. In addition, the mutant protein was found to strongly activate an in vitro reporter construct driven by
the OSR2 promoter, a gene assumed to be a craniofacial target of FOXL2 protein.
Other studies found rare or no FOXL2 sequence variants in phenotypically normal women with POI [De Baere et al 2001, De Baere et al 2002, Harris et al 2002, Bodega et al
2004, Gersak et al 2004, Laissue et al 2009].
Differential Diagnosis
The differential diagnosis of BPES includes those conditions in which ptosis or blepharophimosis is a major feature (Table 2) [Oley & Baraitser 1995]; however, in clinical practice,
blepharophimosis syndrome can be relatively easily distinguished from most of these conditions.
Table 2.
Overview of Conditions in which Ptosis and/or Blepharophimosis is a Prominent Feature
Syndrome MOI Characteristics OMIM
Hereditary congenital ptosis 1 (PTOS1) AD Ptosis 178300
Hereditary congenital ptosis 2 (PTOS2) XL Ptosis 300245
Ohdo blepharophimosis syndrome
AD 
Blepharophimosis
Blepharoptosis
Intellectual disability
Congenital heart defects
Hypoplastic teeth
249620
3MC syndrome 1 (Michels syndrome)
Blepharophimosis
Blepharoptosis
Epicanthus inversus
Ophthalmic anterior segment defects (cornea)
Cleft lip/palate
Minor skeletal abnormalities
257920
Ptosis with external ophthalmoplegia AR
Ptosis
Ophthalmoplegia
Miosis
Decreased accommodation
Strabismus
Amblyopia
258400
Noonan syndrome AD
Ptosis
Short stature
Heart defects
Blood clotting deficiencies
163950
Marden-Walker syndrome
AR
Ptosis
Blepharophimosis
Growth retardation
Neurologic defects (intellectual disability, absent primitive reflexes)
248700
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Syndrome MOI Characteristics OMIM
Schwartz-Jampel syndrome
Intermittent ptosis
Blepharophimosis
Telecanthus
Cataract
Short stature
Cartilage and skeletal anomalies
Muscle hypertrophy
255800
Dubowitz syndrome
Ptosis
Blepharophimosis
Lateral telecanthus
Short stature
Intellectual disability
Immunologic deficiencies
223370
Smith-Lemli-Opitz syndrome
Ptosis
Epicanthus
Cataract
Growth retardation, intellectual disability
Severe genitourinary, cardiac, gastrointestinal anomalies
270400
KANSL1-related intellectual disability syndrome (17q21.31
microdeletion syndrome) AD
Developmental delay with mild-to-moderate intellectual disability
Characteristic facies: long face, high forehead, ptosis, blepharophimosis, large low-set
ears, bulbous nasal tip, pear-shaped nose
Nasal speech
Cardiac septal defects, seizures, cryptorchidism
Friendly disposition
610443
Oley & Baraitser [1995], OMIM
MOI = mode of inheritance
AD = autosomal dominant;
AR = autosomal recessive
XL = X-linked
Presumed mode of inheritance
Gijsbers et al [2008]
Management
Evaluations Following Initial Diagnosis
To establish the extent of disease and needs in an individual diagnosed with blepharophimosis syndrome (BPES), the following evaluations are recommended:
Examination by a (pediatric) ophthalmologist for visual acuity, refractive error, extraocular movement, strabismus, size of palpebral apertures, and eyelid elevation. Those
with amblyopia or strabismus should be referred to a pediatric ophthalmologist for management [Beckingsale et al 2003].
Genetic evaluation and genetic counseling by a clinical geneticist to discuss recurrence risk and assess risk for premature ovarian insufficiency (POI). In girls with BPES, the
family history can indicate the type of BPES in affected females (with type I inferred by the association with subfertility or infertility). In uninformative families or simplex
cases (i.e., single occurrence in a family), molecular genetic testing may be helpful in some cases in assessing the risk for POI.
Referral of females with BPES to a pediatric or adult endocrinologist during late puberty or early adulthood to assess onset and course of POI
Treatment of Manifestations
Management requires the input of specialists including a clinical geneticist, pediatric ophthalmologist, oculoplastic surgeon, (pediatric or adult) endocrinologist, reproductive
endocrinologist, and gynecologist.
Eyelid surgery. Timing of eyelid surgery is controversial; it involves weighing the balance of early surgery to prevent deprivation amblyopia and late surgery to allow for more
reliable ptosis measurements, the latter of which provides a better surgical outcome. Furthermore, ptosis surgery is hampered by the dysplastic structure of the eyelids [Beckingsale
et al 2003].
The surgical management is traditionally performed in two stages and involves a medial canthoplasty for correction of the blepharophimosis, epicanthus inversus, and telecanthus at
ages three to five years, followed about a year later by ptosis correction, which usually requires a brow suspension procedure.
Many surgical techniques have been described for medial canthoplasty and none of the existing methods is free from criticism. If the epicanthal folds are small, a Y-V
canthoplasty is traditionally used; if the epicanthal folds are severe, a double Z-plasty is used. An alternate technique for medial canthoplasty has been described recently
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using the skin redraping method, which has a simple flap design, less scarring, and the effective repair of epicanthus inversus and telecanthus [Sa et al 2012].
To correct telecanthus, the medial canthal tendon is usually shortened or fused with a transnasal wire.
Ptosis correction is particularly important as it can address the disfigurement as well as functional concerns. Frontal muscle flap suspension is mostly used for severe ptosis in
adults; however, it remains controversial. A major concern is that the frontal muscle development may be restrained by surgery. Decock et al [2011b] reported that super-
maximal resection and frontalis suspension is the preferred method as it leads to a good cosmetic outcome as well as to an improved muscle function.
Alternatively, a one-stage procedure in which medial canthoplasty and ptosis correction are performed simultaneously has been described [Wu et al 2008]. Two recent
retrospective, interventional studies including 21 patients demonstrated that one-stage correction using a standard combination of surgical techniques is safe and efficient [Sebastiá
et al 2011, Liu et al 2014].
Recent insights into the causes of the abnormal lower eyelid positioning allow a more targeted surgical reconstruction that produces a more natural appearance [Decock et al
2011a]. Ten individuals with molecularly proven BPES were noted to have a laterally displaced inferior punctum (i.e., in the lower eyelid) due to temporal displacement of the entire
lower eyelid. Addition of a simple surgical step corrected the position of the lower eyelid and its abnormal downward concavity (the temporal ectropion), and the lateral
displacement of the inferior punctum. This approach eliminates the epicanthus inversus fold without the need for double Z-plasty [Decock et al 2011b].
Ovarian insufficiency. Management of premature ovarian insufficiency (POI) needs to address the two following major medical issues that are applicable to primary ovarian
insufficiency in general and not specific for BPES (no data specific to BPES are available):
Hormone replacement therapy (HRT). The American Society for Reproductive Medicine and the International Menopause Society recommend estrogen replacement
therapy for women with primary ovarian insufficiency (amenorrhea and a menopausal serum FSH concentration). Although no data from randomized trials guide the use of
hormonal therapy in women with BPES and POI, a reasonable regimen would be 100 μg of transdermal estradiol and 10 mg of oral medroxyprogesterone acetate daily for
the first 12 days of each month. Women should keep a menstrual calendar and have a pregnancy test promptly in the case of late menses [Nelson 2009].
  
A pelvic ultrasound examination and measurement of bone mineral density are indicated at the time of diagnosis of ovarian insufficiency. Women with primary ovarian
insufficiency should be encouraged to maintain a lifestyle that optimizes bone and cardiovascular health, including engaging in regular weight-bearing exercise, maintaining an
adequate intake of calcium (1200 mg daily) and vitamin D (at least 800 IU daily), eating a healthy diet to avoid obesity, and undergoing screening for cardiovascular risk
factors, with treatment of any identified risk factors.
Infertility. No therapies have been shown to restore ovarian function and fertility. Some couples are averse to adoption and to reproductive technologies and are content
not to become parents.
  
For couples who decide to pursue parenthood actively, the options are adoption, foster parenthood, embryo donation, and egg donation. The rates of pregnancy with egg
donation appear to be similar among older and younger women. Women with primary ovarian insufficiency who become pregnant as a result of oocyte donation may have an
increased risk of delivering infants who are small for gestational age and of having pregnancy-induced hypertension and postpartum hemorrhage, but these findings are
controversial [Nelson 2009].
  
The issue of POI is emotionally charged and should be discussed with the patient with this in mind.
Surveillance
The frequency of ophthalmic follow-up should be individualized depending on age, procedures performed in the past, and results of visual acuity testing.
Endocrinologic and gynecologic follow up are advised in females in whom the BPES type is unknown or in whom BPES type I is suspected based on a positive family history or
FOXL2 pathogenic variant. Frequency of endocrinologic follow-up to monitor ovarian status is individualized and can involve pelvic ultrasound examination, measurement of serum
FSH concentrations, and assessment of menstrual pattern (ages of menarche and onset of oligomenorrhea and secondary amenorrhea).
Evaluation of Relatives at Risk
See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.
Therapies Under Investigation
Ovarian transplantation has been performed in rare instances in which the affected woman has an identical twin sister with normal ovarian function [Nelson 2009].
Note: (1) Cryopreservation has not yet been reported in BPES. (2) Children who are at risk for POI are most likely to benefit from cryopreservation as their ovaries contain more
primordial follicles than those of adult women; it is expected that by the time these children are mature and need their ovarian tissue, the modalities for its optimal use would become
available. (3) At the time that they might wish to consider an IVF procedure, adult women with BPES usually do not have sufficient appropriate primordial follicles for embryo
cryopreservation.
Search ClinicalTrials.gov for access to information on clinical studies for a wide range of diseases and conditions.
Genetic Counseling
Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify
genetic status for family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may face or to substitute for consultation
with a genetics professional. —ED.
Mode of Inheritance
Blepharophimosis, ptosis, and epicanthus inversus syndrome (BPES) is almost always inherited in an autosomal dominant manner. Autosomal recessive inheritance has been
reported in a single consanguineous family [Nallathambi et al 2007].
Risk to Family Members — Autosomal Dominant Inheritance
Parents of a proband
Some individuals diagnosed with autosomal dominant BPES have an affected parent.
A proband with AD BPES may have the disorder as the result of a de novo pathogenic variant.
Recommendations for the evaluation of parents of a proband with an apparent de novo pathogenic variant include molecular genetic testing of FOXL2 if the pathogenic
variant has been identified in the proband and clinical examination for subtle features of BPES.
Note: If the parent is the individual in whom the pathogenic variant first occurred, s/he may have somatic mosaicism for the variant and may be mildly/minimally affected
[unpublished data].
Sibs of a proband
The risk to the sibs of the proband depends on the genetic status of the proband's parents.
If a parent of the proband is affected, the risk to the sibs is 50%.
When the parents are clinically unaffected and do not have a FOXL2 pathogenic variant, the risk to the sibs of a proband appears to be low.
If a FOXL2 pathogenic variant cannot be detected in the DNA of either parent, two possible explanations are germline mosaicism in a parent or a de novo pathogenic
variant in the proband. The risk to the sibs of the proband depends on the probability of germline mosaicism in a parent of the proband and the spontaneous mutation rate of
FOXL2.
Germline mosaicism has been observed in AD BPES and demonstrated at the molecular level [Beysen et al 2005]; its incidence is unknown.
Offspring of a proband. Each child of an individual with AD BPES has a 50% chance of inheriting the pathogenic variant.
Other family members of a proband. The risk to other family members depends on the genetic status of the proband's parents. If a parent is affected, his or her family members
are at risk.
Related Genetic Counseling Issues
Considerations in families with an apparent de novo pathogenic variant. When neither parent of a proband with an autosomal dominant condition has the pathogenic variant
or clinical evidence of the disorder, it is likely that pathogenic variant occurred de novo in the proband. However, possible non-medical explanations including alternate paternity or
undisclosed adoption could also be explored.
Family planning
The optimal time for determination of genetic risk and discussion of the availability of prenatal diagnosis is before pregnancy.
It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected. In addition,
families in which (1) women with BPES have had premature ovarian failure or (2) women with BPES have an unknown risk for premature ovarian insufficiency (POI) should
be informed regarding this risk so that they may consider early childbearing.
DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of
genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.
Prenatal Testing and Preimplantation Genetic Diagnosis
Once the FOXL2 pathogenic variant has been identified in an affected family member, prenatal testing and preimplantation genetic diagnosis for a pregnancy at increased risk for
BPES are possible options.
Requests for prenatal testing for conditions such as BPES are not common. Differences in perspective may exist among medical professionals and within families regarding the use
of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider
decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.
Resources
GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click here.
AboutFace International
123 Edward Street
Suite 1003
Toronto Ontario M5G 1E2
Canada
Phone: 800-665-3223 (toll-free); 416-597-2229
Fax: 416-597-8494
Email: info@aboutfaceinternational.org
www.aboutfaceinternational.org
Children's Craniofacial Association (CCA)
13140 Coit Road
Suite 517
Dallas TX 75240
Phone: 800-535-3643 (toll-free); 214-570-9099
Fax: 214-570-8811
Email: contactCCA@ccakids.com
www.ccakids.com
FACES: The National Craniofacial Association
PO Box 11082
Chattanooga TN 37401
Phone: 800-332-2373 (toll-free)
Email: faces@faces-cranio.org
www.faces-cranio.org
National Foundation for Facial Recontruction (NFFR)
317 East 34th Street
Room 901
New York NY 10016
Phone: 212-263-6656
Fax: 212-263-7534
Email: info@nffr.org
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www.nffr.org
Molecular Genetics
Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.
Table A.
Blepharophimosis, Ptosis, and Epicanthus Inversus: Genes and Databases
Gene Chromosome Locus Protein Locus-Specific Databases HGMD ClinVar
FOXL2 3q22 .3 Forkhead box protein L2 FOXL2 homepage - FOXL2 @ LOVD FOXL2 FOXL2
Data are compiled from the following standard references: gene from HGNC; chromosome locus from OMIM; protein from UniProt. For a description of databases (Locus Specific, HGMD,
ClinVar) to which links are provided, click here.
Table B.
OMIM Entries for Blepharophimosis, Ptosis, and Epicanthus Inversus (View All in OMIM)
110100 BLEPHAROPHIMOSIS, PTOSIS, AND EPICANTHUS INVERSUS; BPES
605597 FORKHEAD TRANSCRIPTION FACTOR FOXL2; FOXL2
Gene structure. FOXL2 is a small single-exon gene of 2.7 kb. The entire open reading frame is highly conserved in several vertebrate species [Cocquet et al 2002, Cocquet et al
2003, Udar et al 2003]. For a detailed summary of gene and protein information, see Table A, Gene.
Benign allelic variants. The normal alleles have 14 copies of the Ala repeat, p.Ala221[14]. See Table 3.
Table 3.
Selected FOXL2 Benign Variants
DNA Nucleotide Change Protein Amino Acid Change Reference Sequences
See footnote 1 p.Ala221[14] NM_023067 .3 NP_075555 .1
Note on variant classification: Variants listed in the table have been provided by the authors. GeneReviews staff have not independently verified the classification of variants.
Note on nomenclature: GeneReviews follows the standard naming conventions of the Human Genome Variation Society (varnomen .hgvs.org). See Quick Reference for an explanation of
nomenclature.
The polyalanine expansion is an imperfect trinucleotide repeat that may consist of each of the four codons for alanine (GCA, GCC, GCG, GCT). Nucleotide changes resulting in varying
numbers of Ala repeats are described as deletions and duplications (for details see LOVD database).
Indicates that a stretch of alanines (Ala) is present, starting at amino acid position 221. Benign allelic variants are designated as p.Ala221[14] because they have exactly 14 Ala repeat
units.
Pathogenic allelic variants. See Table 4. More than 125 FOXL2 pathogenic variants have been described in individuals with BPES type I and type II, demonstrating that both
phenotypic features (eyelid defect and POI) are caused by the pleiotropic effect of mutation of a single gene, rather than by a contiguous gene syndrome. To date, a total of 106
unique intragenic FOXL2 pathogenic variants (i.e., different pathogenic variants that are unique to the world-wide collection of allelic variants) have been identified in 206 unrelated,
ethnically diverse families with BPES [Beysen et al 2009 and references therein]. Detailed information on most FOXL2 pathogenic variants and affected individuals or families with
BPES is available in the FOXL2 Mutation Database (see Table A). Each family has a unique FOXL2 database identifier (FOXL2db-Id), indicated with a number and the prefix
“FOXL2.”
The occurrence of two mutational hot spots previously described by the author [De Baere et al 2001, De Baere et al 2003] was corroborated by subsequent findings. Pathogenic
variants leading to an expansion of the poly-Ala tract account for 31% (63/206) and the 17-bp duplication c.843_859dup accounts for 13% (26/206) of all intragenic FOXL2
pathogenic variants. Another, less frequent 17-bp duplication c.855_871dup, along with c.841_857dup, c.843_865dup, c.854delC, and c.855_871del17, are all clustered,
perhaps because of the hypermutability of this region. Other less frequent pathogenic variants are c.655C>T and c.804dupC [De Baere et al 2003, Beysen et al 2009].
Larger genomic rearrangements, including deletions involving FOXL2, accounted for 10% of the molecular defects found in families with typical BPES [Beysen et al 2005]. The
extent of the deletions ranges from a partial- and total-gene deletion to microdeletions encompassing FOXL2 and neighboring genes including the Seckel syndrome-associated
gene, ATR, located 5’ to FOXL2 [Beysen et al 2005, D'haene et al 2010]. Cytogenetically detectable deletions include a 7.7-Mb deletion encompassing FOXL2 and ATR in an
individual with BPES with microcephaly and developmental delay [de Ru et al 2005], a deletion of unknown extent in a simplex case involving an individual with BPES and normal
psychomotor development [Or et al 2006], and others reviewed in de Ru et al [2005] and references therein.
Rearrangements outside the FOXL2 transcription unit are estimated to account for 5% of all molecular defects found in BPES [Beysen et al 2005] and implicate an effect of long-
range cis-regulatory elements in regulating FOXL2 expression.
The occurrence of three translocation breakpoints located upstream of FOXL2 [De Baere et al 2000, Praphanphoj et al 2000, Crisponi et al 2004] illustrated that a position
effect may also be implicated in the causation of BPES.
Beysen et al [2005] reported on five FOXL2-extragenic deletions in individuals with typical features of BPES.
D'haene et al [2009] reported four novel regulatory deletions of which one was as small as 7.4 kb and, thus, defines the crucial cis-regulatory region containing the long non-
coding RNA PISRT1.
González-González et al [2012] reported a girl with BPES with a de novo apparently balanced translocation between chromosomes 3 and 15: t(3;15)(q23;q25) and a
62.3-kb deletion at the 3q23 translocation breakpoint encompassing PISRT1.
In a four-generation Chinese family with BPES type II showing linkage to the FOXL2 locus, an insertion in the 3' UTR of FOXL2 segregated with the phenotype. This variant was
shown to be located in an AU-rich repeat; however, the functional significance of this 3' UTR insertion on FOXL2 transcript stability and translation remains to be proven [Qian et
al 2004].
In addition, one 5’ UTR and two 3’ UTR variants were identified in Chinese families with BPES [Li et al 2009]; however, the functional significance of these UTR variants on
FOXL2 transcript stability and translation are not yet demonstrated.
2
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Table 4.
Selected FOXL2 Pathogenic Variants
DNA Nucleotide Change Protein Amino Acid Change Reference Sequences
c.560G>A p.Gly187Asp
NM_023067 .3
 NP_075555 .1
c.650C>T p.Ser217Phe
c.655C>T p.Gln219Ter
See footnote 1 p.Ala221(15_24) 
c.804dupC p.Gly269ArgfsTer265
c.841_857dup p.Pro287ArgfsTer75
c.843_859dup p.Pro287ArgfsTer75
c.843_865dup p.His289ArgfsTer75
c.854delC p.Pro285ArgfsTer71
c.855_871dup p.His291ArgfsTer71
c.855_871del17 p.Pro287AlafsTer241
Note on variant classification: Variants listed in the table have been provided by the authors. GeneReviews staff have not independently verified the classification of variants.
Note on nomenclature: GeneReviews follows the standard naming conventions of the Human Genome Variation Society (varnomen .hgvs.org). See Quick Reference for an explanation of
nomenclature.
Note: The polyalanine expansion does not result from a simple trinucleotide repeat, but often consists of each of the four codons for alanine (GCA, GCC, GCG, GCT). Nucleotide
changes resulting in varying numbers of Ala repeats are described as deletions and duplications (for details see LOVD database).
Indicates that a stretch of alanines (Ala) is present, starting at amino acid position 221, which is found with a variable length from 14 to 24; the underscore is used to indicate the range
(from residue to residue). Benign alleles are designated as p.Ala221[14] because they have exactly 14 Ala repeat units (Table 3); Pathogenic alleles, designated as p.Ala221(15_24), can
have 15 to 24 Ala repeat units (for details see LOVD database).
Normal gene product. The FOXL2 protein of 376 amino acids belongs to the large family of winged-helix/forkhead transcription factors. Forkhead proteins are present in all
eukaryotes and have important functions in the establishment of the body axis and the development of tissues from all three layers in animals. Apart from the following two domains
no similarities to other known proteins or domains have been identified [Crisponi et al 2001].
FOXL2 also contains a characteristic DNA-binding domain of 110 amino acids that was originally identified in Drosophila melanogaster fork head mutant; the domain was
nearly perfectly conserved between fork head and the mammalian HNF-3 transcription factors.
FOXL2 contains a polyalanine tract of 14 residues, the role of which has not yet been elucidated. Expansions from 14 to 24 alanine residues in this region represent about
30% of all intragenic FOXL2 pathogenic variants and lead mainly to BPES type II [De Baere et al 2003].
Click here (pdf) for detailed information on forkhead transcription factor, evolution, expression, subcellular localization, protein interactions.
Abnormal gene product. In general, haploinsufficiency of FOXL2 appears to be the cause of BPES as 82% of pathogenic variants are either intragenic variants or partial/total
deletions of FOXL2 or microdeletions and submicroscopic deletions encompassing FOXL2 and neighboring genes [De Baere et al 2001, De Baere et al 2003, Beysen et al 2005,
Beysen et al 2009, D'haene et al 2010].
In recent years, some insights into the phenotypic effects of FOXL2 pathogenic variants were gained by in vitro studies of several types of natural and artificial FOXL2 variants. It
was shown that the most recurrent polyalanine expansion led to intranuclear aggregation and mislocalization of the protein as a result of extensive cytoplasmic aggregation, whereas
the normal FOXL2 protein exclusively localizes in the nucleus in a diffuse manner [Caburet et al 2004]. Moreover, a dominant-negative effect was demonstrated. Although
polyalanine expansions cause an eyelid phenotype indistinguishable from that caused by other intragenic variants, a mild ovarian phenotype is observed only in a fraction of
heterozygotes. This may be attributed to a difference in functional thresholds or in tissue-specific aggregation of the mutant protein in eyelid mesenchyme and follicular cells, due to
tissue-specific co-aggregation partners [Caburet et al 2004]. In turn, the small polyalanine expansion (19 alanines) only leads to cytoplasmic staining in a minority of transfected
cells and to no detectable aggregation [Nallathambi et al 2007]. Subsequently it was shown that polyalanine expansions lead to protein mislocalization, aggregation and altered
intranuclear mobility in a length-dependent manner. Luciferase assays and real time RT-PCR of several target genes showed that various polyalanine expansions induce differential
downregulation depending on the target promoters analyzed [Moumné et al 2008].
Moreover, it was shown that the steroidogenic acute regulatory gene STAR (StAR), whose protein is a marker of granulosa cell differentiation, is a direct target gene of FOXL2,
acting as a repressor of StAR [Pisarska et al 2004]. Two disease-associated truncating FOXL2 variants (truncation of 93 and 218 amino acids) did not result in complete loss of
repressor activity. In addition, these FOXL2 truncated proteins were shown to exhibit a dominant-negative effect. It was concluded that the entire alanine/proline-rich carboxyl
terminus is important for the repressor activity of FOXL2 and that truncating variants may preferentially lead to BPES and ovarian dysfunction by accelerated differentiation of
granulosa cells and secondary depletion of the primordial follicle pool [Pisarska et al 2004]. The identification of a considerable number of ovarian FOXL2 targets [Batista et al
2007] may be essential to reveal more insight into phenotypic effects of FOXL2 pathogenic variants in the (adult) ovary.
Several artificial (i.e., not naturally occurring or reported pathogenic variants in affected individuals but constructed in vitro) nonsense variants have been shown to lead to the
production of N-terminal truncated proteins by reinitiation of translation downstream of the premature stop codon. They display strong nuclear aggregation, and partial
mislocalization to the cytoplasm. In addition, it was shown that these truncated proteins retain a fraction of the wild-type protein, suggesting a dominant-negative effect. Luciferase
assays with natural nonsense variants demonstrated the importance of the entire alanine/proline-rich carboxyl terminus of FOXL2 for transcriptional repression of the STAR (StAR)
promoter. It was also demonstrated that these pathogenic variants produce a protein with a weak dominant-negative effect [Moumné et al 2005].
The present authors subsequently studied the molecular consequences of 17 naturally occurring FOXL2 missense variants. Most mapped to the conserved DNA-binding forkhead
domain. The subcellular localization and aggregation pattern of the mutant FOXL2 proteins was variable and ranged from a diffuse nuclear distribution (resembling wild-type) to
extensive nuclear aggregation often in combination with cytoplasmic mislocalization and aggregation. The authors also studied the transactivation capacity of the mutant proteins in
FOXL2-expressing cells. Several led to a loss of function, while others are suspected to induce a dominant-negative effect. Interestingly, one variant located outside the forkhead
domain (p.Ser217Phe) appeared to be a hypermorphic allele, i.e. causing an increase in normal gene function, leading to a mild BPES phenotype [Beysen et al 2008b].
Click here (pdf) for detailed information on polled intersex syndrome (PIS) in goat and mouse models, structure, evolution, and expression.
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